112 related articles for article (PubMed ID: 29929923)
1. Thirty-day unplanned hospital readmission in ovarian cancer patients undergoing primary or interval cytoreductive surgery: systematic literature review.
Clark RM; Rice LW; Del Carmen MG
Gynecol Oncol; 2018 Aug; 150(2):370-377. PubMed ID: 29929923
[TBL] [Abstract][Full Text] [Related]
2. Unanticipated 30-day readmission following rectosigmoid resection at the time of cytoreductive surgery in patients with advanced stage ovarian cancer.
Sanders BE; Saharti S; Laus K; Bristow RE; Eskander RN
J Obstet Gynaecol; 2021 Aug; 41(6):956-961. PubMed ID: 33228421
[TBL] [Abstract][Full Text] [Related]
3. Risk factors and indications for 30-day readmission after primary surgery for epithelial ovarian cancer.
AlHilli M; Langstraat C; Tran C; Martin J; Weaver A; McGree M; Mariani A; Cliby W; Bakkum-Gamez J
Int J Gynecol Cancer; 2015 Feb; 25(2):193-202. PubMed ID: 25611896
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemotherapy does not disproportionately influence post-operative complication rates or time to chemotherapy in obese patients with advanced-stage ovarian cancer.
Kanbergs AN; Manning-Geist BL; Pelletier A; Sullivan MW; Del Carmen MG; Horowitz NS; Growdon WB; Clark RM; Muto MG; Worley MJ
Gynecol Oncol; 2020 Dec; 159(3):687-691. PubMed ID: 32951891
[TBL] [Abstract][Full Text] [Related]
5. National trends in bowel and upper abdominal procedures in ovarian cancer surgery.
Dottino JA; He W; Sun CC; Zhao H; Fu S; Rauh-Hain JA; Suidan RS; Lu KH; Giordano SH; Meyer LA
Int J Gynecol Cancer; 2020 Aug; 30(8):1195-1202. PubMed ID: 32616627
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemotherapy is associated with more anemia and perioperative blood transfusions than primary debulking surgery in women with advanced stage ovarian cancer.
O'Shea A; McCool K; Harrison R; Sampene E; Connor J; Barroilhet L
Gynecol Oncol; 2018 Jul; 150(1):19-22. PubMed ID: 29773300
[TBL] [Abstract][Full Text] [Related]
7. Surgical readmission and survival in women with ovarian cancer: Are short-term quality metrics incentivizing decreased long-term survival?
Barber EL; Rossi EC; Gehrig PA
Gynecol Oncol; 2017 Dec; 147(3):607-611. PubMed ID: 28941658
[TBL] [Abstract][Full Text] [Related]
8. Predictive Factors for Surgical Morbidities and Adjuvant Chemotherapy Delay for Advanced Ovarian Cancer Patients Treated by Primary Debulking Surgery or Interval Debulking Surgery.
Castro BGR; Dos Reis R; Cintra GF; Sousa MMA; Vieira MA; Andrade CEMDC
Int J Gynecol Cancer; 2018 Oct; 28(8):1520-1528. PubMed ID: 30036229
[TBL] [Abstract][Full Text] [Related]
9. Beyond post-operative readmissions: analysis of the impact of unplanned readmissions during primary treatment of advanced-stage epithelial ovarian cancer on long-term oncology outcome.
Huang D; Harrison R; Curtis E; Mirabadi N; Chen GY; Alexandridis R; Barroilhet L; Rose S; Hartenbach E; Al-Niami A
Int J Gynecol Cancer; 2023 May; 33(5):741-748. PubMed ID: 36808044
[TBL] [Abstract][Full Text] [Related]
10. Unplanned postoperative intensive care unit admission for ovarian cancer cytoreduction is associated with significant decrease in overall survival.
Ross MS; Burriss ME; Winger DG; Edwards RP; Courtney-Brooks M; Boisen MM
Gynecol Oncol; 2018 Aug; 150(2):306-310. PubMed ID: 29929924
[TBL] [Abstract][Full Text] [Related]
11. Systematic Review of Cytoreductive Surgery and Bevacizumab-Containing Chemotherapy in Advanced Ovarian Cancer: Focus on Safety.
Petrillo M; Nero C; Carbone V; Bruno M; Scambia G; Fagotti A
Ann Surg Oncol; 2018 Jan; 25(1):247-254. PubMed ID: 29134372
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy or primary debulking surgery in FIGO IIIC and IV patients; results from a survey study in the Netherlands.
Timmermans M; Sonke GS; van Driel WJ; Lalisang RI; Ottevanger PB; de Kroon CD; Van de Vijver KK; van der Aa MA; Kruitwagen RF
Eur J Obstet Gynecol Reprod Biol; 2018 Apr; 223():98-102. PubMed ID: 29525755
[TBL] [Abstract][Full Text] [Related]
13. A meta-analysis of morbidity and mortality in primary cytoreductive surgery compared to neoadjuvant chemotherapy in advanced ovarian malignancy.
Bartels HC; Rogers AC; McSharry V; McVey R; Walsh T; O'Brien D; Boyd WD; Brennan DJ
Gynecol Oncol; 2019 Sep; 154(3):622-630. PubMed ID: 31349996
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center.
Mueller JJ; Zhou QC; Iasonos A; O'Cearbhaill RE; Alvi FA; El Haraki A; Eriksson AG; Gardner GJ; Sonoda Y; Levine DA; Aghajanian C; Chi DS; Abu-Rustum NR; Zivanovic O
Gynecol Oncol; 2016 Mar; 140(3):436-42. PubMed ID: 26777991
[TBL] [Abstract][Full Text] [Related]
15. Comparison of patient reported symptom burden on an enhanced recovery after surgery (ERAS) care pathway in patients with ovarian cancer undergoing primary vs. interval tumor reductive surgery.
Meyer LA; Shi Q; Lasala J; Iniesta MD; Lin HK; Nick AM; Williams L; Sun C; Wang XS; Lu KH; Ramirez PT
Gynecol Oncol; 2019 Mar; 152(3):501-508. PubMed ID: 30876495
[TBL] [Abstract][Full Text] [Related]
16. Readmissions after ovarian cancer cytoreduction surgery: The first 30 days and beyond.
Mardock AL; Rudasill SE; Lai TS; Sanaiha Y; Wong DH; Sinno AK; Benharash P; Cohen JG
J Surg Oncol; 2020 Nov; 122(6):1199-1206. PubMed ID: 32700323
[TBL] [Abstract][Full Text] [Related]
17. Factors Associated with Readmission After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis.
Martin AS; Abbott DE; Hanseman D; Sussman JE; Kenkel A; Greiwe P; Saeed N; Ahmad SH; Sussman JJ; Ahmad SA
Ann Surg Oncol; 2016 Jun; 23(6):1941-7. PubMed ID: 26842489
[TBL] [Abstract][Full Text] [Related]
18. Assessment of risk factors for 30-day hospital readmission after surgical cytoreduction in epithelial ovarian carcinoma.
Fauci JM; Schneider KE; Frederick PJ; Wilding G; Consiglio J; Sutton AL; Kilgore LC; Barnes MN
Int J Gynecol Cancer; 2011 Jul; 21(5):806-10. PubMed ID: 21412162
[TBL] [Abstract][Full Text] [Related]
19. Oncologic Concerns regarding Laparoscopic Cytoreductive Surgery in Patients with Advanced Ovarian Cancer Submitted to Neoadjuvant Chemotherapy.
Favero G; Macerox N; Pfiffer T; Köhler C; da Costa Miranda V; Estevez Diz Mdel P; Fukushima JT; Baracat EC; Carvalho JP
Oncology; 2015; 89(3):159-66. PubMed ID: 25968072
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for readmission in patients with ovarian, fallopian tube, and primary peritoneal carcinoma who are receiving front-line chemotherapy on a clinical trial (GOG 218): an NRG oncology/gynecologic oncology group study (ADS-1236).
Duska LR; Java JJ; Cohn DE; Burger RA
Gynecol Oncol; 2015 Nov; 139(2):221-7. PubMed ID: 26335594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
